American Society of Clinical OncologyRevised Neuroblastoma Risk Classification System: A Report from the Children’s Oncology Group

It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.

American Society of HematologyCaloric and Nutrient Restriction to Augment Chemotherapy Efficacy for Acute Lymphoblastic Leukemia: the IDEAL Trial

From the pages of Blood Advances comes this Clinical Trials & Observations piece discussing the IDEAL trial. Backed by visual abstracts, tables, and charts supporting the data, the article explores two key points in augmenting chemotherapy efficacy: caloric restriction and using insulin and adiponectin as potential biomarkers of B-ALL chemosensitivity.